{
  "id": "5a7617b183b0d9ea66000022",
  "type": "factoid",
  "question": "What is inhibited by a drug rilotumumab?",
  "ideal_answer": "Rilotumumab is a fully human monoclonal antibody that selectively targets the hepatocyte growth factor (HGF). It is used for treatment of cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27568322",
    "http://www.ncbi.nlm.nih.gov/pubmed/28472537",
    "http://www.ncbi.nlm.nih.gov/pubmed/28280216",
    "http://www.ncbi.nlm.nih.gov/pubmed/27966237",
    "http://www.ncbi.nlm.nih.gov/pubmed/28958504",
    "http://www.ncbi.nlm.nih.gov/pubmed/28209746",
    "http://www.ncbi.nlm.nih.gov/pubmed/25712685",
    "http://www.ncbi.nlm.nih.gov/pubmed/24186235",
    "http://www.ncbi.nlm.nih.gov/pubmed/23136195"
  ],
  "snippets": [
    {
      "text": "The hepatocyte growth factor receptor (MET) was targeted in untreated patients in a phase III trial with MoAb rilotumumab, with or without CT, but the study was stopped because of mortality excess in the rilotumumab arm. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: Rilotumumab is a fully human monoclonal antibody investigated for the treatment of MET-positive gastric cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27966237",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The hepatocyte growth factor (HGF) binding antibody rilotumumab (AMG102) was modified for use as a89Zr-based immuno-PET imaging agent to noninvasively determine the local levels of HGF protein in tumors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280216",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, negative study data have been published for rilotumumab and ficlatuzumab, both of which block hepatocyte growth factor binding to the mesenchymal-epithelial transition (MET) receptor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28209746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this phase 1/2 trial, rilotumumab (an anti-HGF antibody) combined with erlotinib was evaluated in patients with metastatic, previously treated non-small cell lung cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28472537",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28958504",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rilotumumab is an investigational, fully human, monoclonal antibody immunoglobulin G2 against hepatocyte growth factor (HGF) that blocks the binding of HGF to its receptor MET and has shown trends toward improved survival in a phase 2 clinical trial in gastric cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24186235",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE Rilotumumab is an investigational, fully human monoclonal antibody to hepatocyte growth factor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25712685",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor (HGF)/scatter factor, combined with mitoxantrone and prednisone (MP) in patients with castration-resistant prostate cancer (CRPC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23136195",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28958504",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "hepatocyte growth factor"
}